| Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | C$ 0.00 | C$ 0.00 |
| Gross Profit | $ 0.00 | $ -4.27K | $ -240.00 | C$ 0.00 | C$ 0.00 |
| Operating Income | $ -6.24M | $ -3.66M | $ -2.75M | C$ -4.38M | C$ -334.29K |
| EBITDA | $ -6.92M | $ 1.03M | $ -51.11M | C$ 10.77M | C$ 10.49M |
| Net Income | $ -6.94M | $ 1.01M | $ -51.16M | C$ 8.01M | C$ 8.23M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 7.44M | $ 6.14M | $ 762.80K | C$ 15.96K | C$ 431.90K |
| Total Assets | $ 17.57M | $ 7.32M | $ 1.13M | C$ 258.93M | C$ 326.55M |
| Total Debt | $ 0.00 | $ 0.00 | $ 10.45M | C$ 685.00K | C$ 0.00 |
| Net Debt | $ -7.44M | $ -6.14M | $ 9.69M | C$ 669.04K | C$ -431.90K |
| Total Liabilities | $ 623.19K | $ 594.37K | $ 12.10M | C$ 14.27M | C$ 16.38M |
| Stockholders' Equity | $ 16.94M | $ 6.72M | $ -10.97M | C$ 244.66M | C$ 236.65M |
| Cash Flow | |||||
| Free Cash Flow | $ -8.64M | $ -3.74M | $ -2.95M | C$ -519.60K | C$ -839.17K |
| Operating Cash Flow | $ -8.14M | $ -3.73M | $ -2.95M | C$ -519.60K | C$ -839.17K |
| Investing Cash Flow | $ -4.51M | $ -16.23K | $ -5.73K | C$ 0.00 | C$ -32.04K |
| Financing Cash Flow | $ 13.96M | $ 9.15M | $ 2.35M | C$ 1.59K | C$ -1.63M |
Psyence Biomedical Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.